Literature DB >> 22419691

Mammalian target of rapamycin and the kidney. I. The signaling pathway.

Wilfred Lieberthal1, Jerrold S Levine.   

Abstract

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays a fundamental role in regulating cellular homeostasis and metabolism. In a two-part review, we examine the complex molecular events involved in the regulation and downstream effects of mTOR, as well as the pivotal role played by this kinase in many renal diseases, particularly acute kidney injury, diabetic nephropathy, and polycystic kidney diseases. Here, in the first part of the review, we provide an overview of the complex signaling events and pathways governing mTOR activity and action. mTOR is a key component of two multiprotein complexes, known as mTOR complex 1 (mTORC1) and 2 (mTORC2). Some proteins are found in both mTORC1 and mTORC2, while others are unique to one or the other complex. Activation of mTORC1 promotes cell growth (increased cellular mass or size) and cell proliferation (increased cell number). mTORC1 acts as a metabolic "sensor," ensuring that conditions are optimal for both cell growth and proliferation. Its activity is tightly regulated by the availability of amino acids, growth factors, energy stores, and oxygen. The effects of mTORC2 activation are distinct from those of mTORC1. Cellular processes modulated by mTORC2 include cell survival, cell polarity, cytoskeletal organization, and activity of the aldosterone-sensitive sodium channel. Upstream events controlling mTORC2 activity are less well understood than those controlling mTORC1, although growth factors appear to stimulate both complexes. Rapamycin and its analogs inhibit the activity of mTORC1 only, and not that of mTORC2, while the newer "catalytic" mTOR inhibitors affect both complexes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22419691     DOI: 10.1152/ajprenal.00014.2012

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  32 in total

1.  From TOR and SMAD, why HIF-1α can be bad.

Authors:  David Sheikh-Hamad
Journal:  Am J Physiol Renal Physiol       Date:  2013-09-18

Review 2.  TGF-β: the master regulator of fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2016-04-25       Impact factor: 28.314

Review 3.  Renoprotective approaches and strategies in acute kidney injury.

Authors:  Yuan Yang; Meifang Song; Yu Liu; Hong Liu; Lin Sun; Youming Peng; Fuyou Liu; Manjeri A Venkatachalam; Zheng Dong
Journal:  Pharmacol Ther       Date:  2016-04-22       Impact factor: 12.310

4.  Apoptotic cells activate AMP-activated protein kinase (AMPK) and inhibit epithelial cell growth without change in intracellular energy stores.

Authors:  Vimal A Patel; Donald Massenburg; Snezana Vujicic; Lanfei Feng; Meiyi Tang; Natalia Litbarg; Angelika Antoni; Joyce Rauch; Wilfred Lieberthal; Jerrold S Levine
Journal:  J Biol Chem       Date:  2015-07-16       Impact factor: 5.157

Review 5.  Overnutrition, mTOR signaling, and cardiovascular diseases.

Authors:  Guanghong Jia; Annayya R Aroor; Luis A Martinez-Lemus; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-09-24       Impact factor: 3.619

Review 6.  Tuberous sclerosis complex: the past and the future.

Authors:  Liesbeth De Waele; Lieven Lagae; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2014-12-23       Impact factor: 3.714

7.  Polycystin-1 and Gα12 regulate the cleavage of E-cadherin in kidney epithelial cells.

Authors:  Jen X Xu; Tzong-Shi Lu; Suyan Li; Yong Wu; Lai Ding; Bradley M Denker; Joseph V Bonventre; Tianqing Kong
Journal:  Physiol Genomics       Date:  2014-12-09       Impact factor: 3.107

8.  Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.

Authors:  Djalila Mekahli; Jean-Paul Decuypere; Eva Sammels; Kirsten Welkenhuyzen; Joost Schoeber; Marie-Pierre Audrezet; Anniek Corvelyn; Georges Dechênes; Albert C M Ong; Martijn J Wilmer; Lambertus van den Heuvel; Geert Bultynck; Jan B Parys; Ludwig Missiaen; Elena Levtchenko; Humbert De Smedt
Journal:  Pflugers Arch       Date:  2013-11-06       Impact factor: 3.657

9.  Gα12 is required for renal cystogenesis induced by Pkd1 inactivation.

Authors:  Yong Wu; Jen X Xu; Wassim El-Jouni; Tzongshi Lu; Suyan Li; Qingyi Wang; Mei Tran; Wanfeng Yu; Maoqing Wu; Ivan E Barrera; Joseph V Bonventre; Jing Zhou; Bradley M Denker; Tianqing Kong
Journal:  J Cell Sci       Date:  2016-08-05       Impact factor: 5.285

10.  Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.

Authors:  William E Braun; Jesse D Schold; Brian R Stephany; Rita A Spirko; Brian R Herts
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.